Clinical trials: PD-1 Inhibitors
TNBC - Triple-Negative Breast Cancer
A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
This review will evaluate the efficacy and safety of SHR1210 (Camrelizumab) and antivascular drug(Famitinib) in combination with anthracyclines/taxane-based adjuvant chemotherapy (carrelizumab + FAM + EC-P) compared with…
- Trial name
- NCT05862064
- Testing
- epirubicin,cyclophosphamide,paclitaxel,Carrelizumab, epirubicin,cyclophosphamide,paclitaxel
- Where
- China
- Volunteers
- 606 people
- Sponsor
- Fudan University
Cancer, Immune System Disorder
Montreal Immune-Related Adverse Events (MIRAE) Study
Immune checkpoint inhibitors (ICI) are among the most promising approaches to fighting cancer. However, a substantial percentage of patients experience off-target adverse effects in the form of mild to severe inflammation in…
- Conditions
- Cancer, Immune System Disorder, Inflammatory Reaction, Autoimmune Diseases
- Trial name
- MIRAE (NCT05139706)
- Where
- Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Hepatocellular Carcinoma, Liver Neoplasms
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death that ranks sixth in terms of incident cases, with an overall 5 years survival of 18%.
- Conditions
- Hepatocellular Carcinoma, Liver Neoplasms, Digestive System Neoplasms, Sorafenib
- Trial name
- NCT04518852
- Testing
- TACE combined with sorafenib and PD-1 mAb
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Esophageal Cancer
PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy
This study is a randomized, multi-center, open-label, phase II study of a PD-1 inhibitor (INCMGA00012) versus observation as consolidation therapy after definitive concurrent chemoradiotherapy in patients with locally advanced…
- Trial name
- RHAPSODY (NCT04494009)
- Testing
- INCMGA00012
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Asan Medical Center
Esophageal Squamous Cell Carcinoma
PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC
Concurrent chemoradiotherapy is now considered to be the standard treatment modality for esophageal cancer patients who are medically unfit for surgery.
- Trial name
- NCT06186609
- Testing
- PD-1 inhibitor 200mg per three to four weeks, for one year
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Affiliated Hospital of Nantong University
Advanced Solid Tumor
Study on the Treatment of Advanced Malignant Solid Tumor With Revottack and PD-1 Inhibitor
This is a one arm, open clinical pharmacological exploration study initiated by researchers to evaluate the safety and effectiveness of vesicular stomatitis oncolytic virus injection (Revottack) combined with PD-1 inhibitor in…
- Trial name
- NCT05644509
- Testing
- Oncolytic Virus Injection（Revottack）+PD-1
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Gastric Cancer Stage IV
Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer
This is a single-arm, phase II study aiming to evaluate the feasibility and efficacy of sintilimab (PD-1 inhibitor) in combination of apatinib and two-drug chemotherapy (S-1 plus nab-paclitaxel) as conversion therapy in patients…
- Trial name
- NCT04267549
- Testing
- sintilimab, apatinib, S1
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Tear Disorder, Resectable Locally Advanced Non-Squamous NSCLC
A Prospective Trial of SFI Plus PD-1 Inhibitors and PBC in Resectable NSCLC (SFI-NSCLC)
This prospective, single-center clinical trial will enroll 30 treatment-naïve patients with locally advanced, resectable stage II-IIIA non-small cell lung cancer (NSCLC) to receive neoadjuvant Shenqi Fuzheng Injection (SFI) in…
- Trial name
- SFI-NSCLC (NCT07843251)
- Testing
- Shenqi Fuzheng Injection
- Volunteers
- 30 people
- Sponsor
- Anhui Provincial Cancer Hospital
Lung Cancer
Chromosomal Instability as a Surrogate Biomarker of Drug Resistance in Immunotherapy for Lung Cancer Patients
PD1, as an immune checkpoint inhibitor, has provided a new therapeutic approach for patients with cancer, including patients. Although immunotherapy has proven effective, most patients do not benefit from it because of a large…
- Trial name
- CINSBDRILCP (NCT04203095)
- Testing
- the level of plasma cfDNA CINs
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Nasopharyngeal Neoplasms, PD-1 Inhibitor
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
This prospective, phase II, multicenter, randomized controlled study aims to compare the complete response rate and long-term survival outcomes of two-cycle and three-cycle induction therapy with modified TPF regimens combined…
- Conditions
- Nasopharyngeal Neoplasms, PD-1 Inhibitor, Induction Therapy, Complete Response
- Trial name
- NCT06811844
- Testing
- Two-cycle induction chemotherapy + immunotherapy, Three-cycle induction chemotherapy + immunotherapy
- Where
- 3 sites in China
- Volunteers
- 208 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Melanoma Stage III, Melanoma (Skin)
A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma
This study is an open-label, randomized, comparative phase III study, which will include subjects with resectable stage III skin melanoma (up to 3 resectable transient metastases are acceptable).
- Trial name
- NEO-MIMAJOR (NCT05751928)
- Testing
- BCD-217, anti-PD1, Excision of the primary lesion
- Where
- 36 sites in Belarus, Russia
- Volunteers
- 411 people
- Sponsor
- Biocad
Lung Neoplasm, Small Cell Lung Cancer
Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.
Small cell lung cancer is a highly malignant tumor, and its first-line treatment has not broken through platinum-containing dual-drug chemotherapy in the past 30 years.
- Conditions
- Lung Neoplasm, Small Cell Lung Cancer, PD-1 Inhibitors
- Trial name
- NCT04490421
- Testing
- Camrelizumab combined with Apatinib, Etoposide and Cisplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Fuzhou General Hospital
Metastatic Non-small Cell Lung Cancer
Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer
This is a prospective, single-center, open-label investigator-initiated study designed to evaluate the safety, tolerability, radiation dosimetry, biodistribution, and preliminary antitumor activity of [177Lu]Lu-RTX-2358 in…
- Trial name
- NCT07689643
- Testing
- [177Lu]Lu-RTX-2358
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Non-small Cell Lung Cancer Stage IIIB/IV
Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor
Oral chemotherapeutic drugs were analyzed in patients with driver gene negative locally advanced/advanced non-small cell lung cancer with PS score 2 A prospective, single-arm, multicenter, observational study on the efficacy and…
- Trial name
- NCT06310915
- Testing
- Navelbine oral,Pembrolizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Locally Advanced Hypopharyngeal Carcinoma
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma
The purpose of this clinical trial is to evaluate the efficacy and safety of immunotherapy combined with cetuximab and platinum neoadjuvant therapy in patients with resectable locally advanced hypopharyngeal cancer.
- Trial name
- NCT06151743
- Testing
- three cycles (toripalimab + cetuximab + platinum), Radical surgery, Radiotherapy or chemoradiotherapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Metastatic Solid Tumor
PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.
Finding an effective treatment to rescue with resistance of PD-1/PD-L1 inhibitor has been an urgent problem.The PRaG trial as a salvage therapy in advanced solid tumors has obtained satisfactory results.We found that patients…
- Trial name
- NCT05530200
- Testing
- Hypofractionated radiotherapy, PD-L1 inhibitor, GM-CSF
- Volunteers
- 56 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Hepatocellular Carcinoma
Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and efficacy of Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
- Trial name
- NCT07157306
- Testing
- Gecacitinib Combined With Donafenib and PD-1 Inhibitor
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Solid Tumor, Bladder Cancer
LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors
This is a Phase 1/2, open-label, multi-center, single arm basket study evaluating the administration of lerapolturev ± anti programmed cell death protein 1 (PD 1)/programmed death-ligand 1 (PD L1) monoclonal antibody (mAb) (which…
- Conditions
- Solid Tumor, Bladder Cancer, Non-muscle-invasive Bladder Cancer
- Trial name
- NCT04690699
- Testing
- Lerapolturev, 5% DDM
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Istari Oncology, Inc.
Locally Advanced Colon Cancer
Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C)
The study evaluates the combination of immunotherapy of PD-1 antibody and chemotherapy and neoadjuvant short-course radiotherapy in locally advanced colon cancer (LACC).
- Trial name
- TORCH-C (NCT05732493)
- Testing
- Serplulimab, short-term radiotherapy, Oxaliplatin
- Volunteers
- 120 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC
Hepatocellular carcinoma patients are mostly diagnosed at locally advanced stage. Nowadays, hepatic artery interventional therapy and/or systemic therapy are the main treatments options for these patients.
- Trial name
- HAICPD1-HCC (NCT03869034)
- Testing
- HAIC+PD1, HAIC
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University